Medaffcon's Expertise and Commitment Driving Customer Success in 2023

Home > All articles > Medaffcon’s Expertise and Commitment Driving Customer Success in 2023

Medaffcon’s Expertise and Commitment Driving Customer Success in 2023

Medaffcon takes pride in its dedicated team of RWE and Data Analysts, who bring with them a wealth of expertise and a decade-long track record.

We offer comprehensive support for a wide range of RWE projects, making Medaffcon a trusted partner in the ever-evolving landscape of healthcare research and development. With 35 publications and a remarkable success rate of over 370 projects delivered to leading pharma companies from 2022-2023, our proven track record speaks for itself.

Key Numbers:

  • Expert Team:
    A collective experience of 30 professionals’ spans across Real World Evidence, Market Access, and Medical Affairs teams in 2022 and 2023, ensure a holistic approach to our projects.
  • Specialized Focus:
    In 2023, our RWE & Data Teams have 14 specialists dedicated exclusively to Real World Evidence (RWE) studies, ensuring in-depth insights and solutions.
  • Project Portfolio:
    Currently engaged in 75 ongoing RWE projects and 12 Real World Evidence publications produced in 2023.
  • National and In-House Capabilities:
    Leveraging Swedish healthcare registries and maintaining in-house capabilities for real-world data in Sweden, we enhance the precision and reliability of our research.
  • Support Teams:
    Our Sales, Marketing, and Admin teams, consisting of 6 dedicated members, ensure seamless coordination, allowing our experts to focus on delivering exceptional results.
  • Client Satisfaction:
    Demonstrating our commitment to excellence, our Net Promoter Score is 75

Check Out the Video.

Key Facts from Medaffcon

Explore our expertise and accomplishments. If you are interested to know more, please contact us:
info@medaffcon.fi

Related articles

Jarmo Hahl

Jarmo Hahl

Principal Consultant

MSc (Economics)

+358 40 139 4001

Jarmo joined Medaffcon as a partner and CEO in 2010, having previously worked in various expert and management positions in pharma companies for eight years. Jarmo has a degree in economics and before entering the pharmaceutical industry, he held an office at the Turku School of Economics and also worked as a research fellow at Turku University Hospital.

Jarmo has strong expertise in new health technology innovations and how the demands and expectations of authorities, markets and customers are matched. He also brings to Medaffcon extensive experience in health economics and its applications in research and commercialization, as well as a broad understanding of the ever-changing operating environment.

“From an access point of view, the Finnish health technology market is constantly becoming more demanding and therefore also more attractive from my point of view. On the other hand, increasing demands to demonstrate the effectiveness and cost-effectiveness of healthcare are broadening the scope and opportunities for Medaffcon to be involved in the development of healthcare as a whole”.

Tomi Vahevaara

Tomi Vahevaara

Sales Lead

eMBA

+358 50 305 5963

Tomi Vahevaara started working at Medaffcon in January 2017 as a Sales Director. He has been working in the pharmaceutical industry for over 35 years. Therefore, he has gained wide-ranging experience in international expert and managerial positions within the innovative pharmaceutical industry. Before joining Medaffcon, Tomi worked for ten years as the Managing Director of Eli Lilly for Finland, the Baltic States, and Poland.

Tomi has solid and wide-ranging expertise in different positions in the pharmaceutical field and is well connected in the entire health industry network. He serves as the Chairman of the Board of the Finnish Mutual Insurance Company for Pharmaceutical Injury Indemnities and as a Board Member in the Finnish Co-operative for Pharmaceutical Injury Indemnities. Tomi is particularly interested in the significant economic and investment opportunities for Finland and those companies working in the Finnish health industry.

Petri Määttä

Petri Määttä

Sr. Consultant

BBA

+358 40 355 6111

Petri joined Medaffcon in 2022 as a consultant. Petri holds extensive experience in the pharmaceutical industry especially in Market Access, sales and marketing. Before joining Medaffcon Petri worked in various managerial roles in the pharmaceutical industry which has provided him with a comprehensive understanding of the challenges and opportunities in the field. Petri conducted his BBA studies in the Netherlands and Finland providing him with a great basis to work in international organizations.
Petri’s extensive experience in the pharmaceutical industry and his background in business equip him with a unique perspective in the field of Life Science and commercialization of medicines in Finland. His main focus is on helping companies bring Life Science innovations and services to the Finnish market. Petri’s expertise in Market Access, sales and marketing as well as his deep understanding of the pharmaceutical industry provide Medaffcon’s team with valuable information as they provide customer solutions.
“Resource challenges alongside technological development and digitalization provide considerable opportunities to enhance healthcare in Finland. As data collection and digitalization develop, the effectiveness of health technologies can be demonstrated more precisely. While advanced health technologies and medicine offer more effective treatments, bringing them to the market require special know-how and understanding. Thus, companies, the research sector and governmental agencies should continue to further co-operation in effectively bringing health technologies and medicines to the market while simultaneously managing resource allocation in a rational manner.”